| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ozge Polat Korkmaz, Mert Gurcan, Fatma Eda Nuhoglu Kantarci, Ozlem Haliloglu, Hande Mefkure Ozkaya, Serdar Sahin, Meryem Merve Oren, Necmettin Tanriover, Nurperi Gazioglu, Pinar Kadiogl. The effects of pre-operative somatostatin analogue therapy on treatment cost and remission in acromegaly. Pituitary. vol 22. issue 4. 2020-01-13. PMID:31098838. |
to investigate the effects of preoperative somatostatin analogue (ssa) treatment on the annual cost of all acromegaly treatment modalities and on remission rates. |
2020-01-13 |
2023-08-13 |
Not clear |
| Valentina Zunino, Maria Graziella Catalano, Francesco Zenga, Federica Penner, Francesca Maletta, Francesco Valerio, Letizia Rinella, Emanuela Arvat, Nicoletta Fortunat. Benzene affects the response to octreotide treatment of growth hormone secreting pituitary adenoma cells. Environmental research. vol 173. 2019-12-23. PMID:30986651. |
somatostatin analogs are the gold standard of medical therapy; however, resistance represents a big drawback in acromegaly management. |
2019-12-23 |
2023-08-13 |
human |
| Carla Scaroni, Nora Albiger, Andrea Daniele, Francesca Dassie, Chiara Romualdi, Giovanni Vazza, Daniela Regazzo, Francesco Ferraù, Valeria Barresi, Valeria Maffeis, Marina Paola Gardiman, Salvatore Cannavò, Pietro Maffei, Filippo Ceccato, Marco Losa, Gianluca Occh. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly. The Journal of clinical endocrinology and metabolism. vol 104. issue 3. 2019-12-17. PMID:30285115. |
paradoxical gh increase during ogtt is associated with first-generation somatostatin analog responsiveness in acromegaly. |
2019-12-17 |
2023-08-13 |
Not clear |
| Ammar Muhammad, Eva C Coopmans, Federico Gatto, Sanne E Franck, Joseph A M J L Janssen, Aart Jan van der Lely, Leo J Hofland, Sebastian J C M M Negger. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression. The Journal of clinical endocrinology and metabolism. vol 104. issue 3. 2019-12-17. PMID:30346538. |
pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. |
2019-12-17 |
2023-08-13 |
Not clear |
| Ammar Muhammad, Eva C Coopmans, Federico Gatto, Sanne E Franck, Joseph A M J L Janssen, Aart Jan van der Lely, Leo J Hofland, Sebastian J C M M Negger. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression. The Journal of clinical endocrinology and metabolism. vol 104. issue 3. 2019-12-17. PMID:30346538. |
the response to first-generation somatostatin receptor ligands (srls) treatment in acromegaly correlates with expression of somatostatin receptor subtype 2 (sstr2). |
2019-12-17 |
2023-08-13 |
Not clear |
| b' F Ferra\\xc3\\xb9, P D Romeo, S Puglisi, M Ragonese, F Spagnolo, C Salpietro, R Ientile, M Curr\\xc3\\xb2, G Visalli, A Alibrandi, I A M Picerno, S Cannav\\xc3\\xb. GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly. Journal of endocrinological investigation. vol 42. issue 7. 2019-12-11. PMID:30488289.' |
gstp1 gene methylation and ahr rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly. |
2019-12-11 |
2023-08-13 |
Not clear |
| b' F Ferra\\xc3\\xb9, P D Romeo, S Puglisi, M Ragonese, F Spagnolo, C Salpietro, R Ientile, M Curr\\xc3\\xb2, G Visalli, A Alibrandi, I A M Picerno, S Cannav\\xc3\\xb. GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly. Journal of endocrinological investigation. vol 42. issue 7. 2019-12-11. PMID:30488289.' |
in this study, we assessed the contribution of gstp1 gene promoter methylation status, per se or in combination with the occurrence of the ahr gene rs2066853 variant, on clinical features and response to somatostatin analogs (ssa) treatment in acromegaly patients. |
2019-12-11 |
2023-08-13 |
Not clear |
| Jacqueline Trouillas, Alexandre Vasiljevic, Marion Lapoirie, Laura Chinezu, Emmanuel Jouanneau, Gérald Ravero. Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment. Minerva endocrinologica. vol 44. issue 2. 2019-12-06. PMID:30531694. |
acromegaly is mainly due to the somatotroph pituitary neuroendocrine tumors (pitnet)s. these have been subtyped into densely granulated (dg) and sparsely granulated (sg) tumors, which differ in clinical, histological and biological characteristics and in response to somatostatin analogs (sa)s. the variable remission rate after surgical resection, as first line treatment, has increased interest in identifying pathological markers to better predict the response to medical treatment. |
2019-12-06 |
2023-08-13 |
Not clear |
| Antonio C Fuentes-Fayos, Araceli García-Martínez, Aura D Herrera-Martínez, Juan M Jiménez-Vacas, Mari C Vázquez-Borrego, Justo P Castaño, Antonio Picó, Manuel D Gahete, Raúl M Luqu. Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. Minerva endocrinologica. vol 44. issue 2. 2019-12-06. PMID:30650942. |
treatment with available synthetic somatostatin analogues (ssas) is considered the mainstay in the medical management of acromegaly which exert their beneficial effects through the binding to a family of g-protein coupled receptors encoded by 5 genes (sstr1-5). |
2019-12-06 |
2023-08-13 |
Not clear |
| Seyfullah Kan, Muhammed Kizilgul, Bulent Celik, Selvihan Beysel, Mustafa Caliskan, Mahmut Apaydin, Bekir Ucan, Erman Caka. The effect of disease activity on thyroid nodules in patients with acromegaly. Endocrine journal. vol 66. issue 4. 2019-12-06. PMID:30745501. |
there is no study investigating the impact of somatostatin analog (ssa) treatment on thyroid nodule volume in patients with acromegaly. |
2019-12-06 |
2023-08-13 |
Not clear |
| Chunying Ma, Miao Chen, Weiming Chu, Jiayi Tao, Delong Kong, Mengmeng Zhang, Wenhua Fen. A Practical and Total Synthesis of Pasireotide: Synthesis of Cyclic Hexapeptide via a Three-Component Condensation. Molecules (Basel, Switzerland). vol 24. issue 11. 2019-12-02. PMID:31212595. |
pasireotide is a multi-receptor ligand somatostatin analogue approved for medical treatment of cushing's disease and acromegaly. |
2019-12-02 |
2023-08-13 |
Not clear |
| Sabrina Chiloiro, Gherardo Mazziotti, Antonella Giampietro, Antonio Bianchi, Stefano Frara, Marilda Mormando, Alfredo Pontecorvi, Andrea Giustina, Laura De Marini. Correction to: Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary. vol 21. issue 3. 2019-11-20. PMID:29473124. |
correction to: effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. |
2019-11-20 |
2023-08-13 |
Not clear |
| Rosa Maria Paragliola, Roberto Salvator. Novel Somatostatin Receptor Ligands Therapies for Acromegaly. Frontiers in endocrinology. vol 9. 2019-11-20. PMID:29563895. |
novel somatostatin receptor ligands therapies for acromegaly. |
2019-11-20 |
2023-08-13 |
Not clear |
| Rosa Maria Paragliola, Roberto Salvator. Novel Somatostatin Receptor Ligands Therapies for Acromegaly. Frontiers in endocrinology. vol 9. 2019-11-20. PMID:29563895. |
somatostatin receptor ligands (srls) octreotide (oct), lanreotide, and the more recently approved pasireotide, characterized by a broader receptor ligand binding profile, are considered the mainstay in the medical management of acromegaly. |
2019-11-20 |
2023-08-13 |
Not clear |
| Alessia Cozzolino, Tiziana Feola, Ilaria Simonelli, Giulia Puliani, Carlotta Pozza, Elisa Giannetta, Daniele Gianfrilli, Patrizio Pasqualetti, Andrea Lenzi, Andrea M Isidor. Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-analysis of Prospective Interventional Studies. The Journal of clinical endocrinology and metabolism. 2019-11-20. PMID:29590371. |
somatostatin analogs and glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. |
2019-11-20 |
2023-08-13 |
Not clear |
| Alessia Cozzolino, Tiziana Feola, Ilaria Simonelli, Giulia Puliani, Carlotta Pozza, Elisa Giannetta, Daniele Gianfrilli, Patrizio Pasqualetti, Andrea Lenzi, Andrea M Isidor. Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-analysis of Prospective Interventional Studies. The Journal of clinical endocrinology and metabolism. 2019-11-20. PMID:29590371. |
somatostatin analogs (ssas) effectivelycontrol growth hormone secretion in first and second line treatmentof acromegaly. |
2019-11-20 |
2023-08-13 |
Not clear |
| Ludovica F S Grasso, Renata S Auriemma, Rosario Pivonello, Annamaria Cola. Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly. Expert review of endocrinology & metabolism. vol 12. issue 1. 2019-11-20. PMID:30058878. |
somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly. |
2019-11-20 |
2023-08-13 |
Not clear |
| Ludovica F S Grasso, Renata S Auriemma, Rosario Pivonello, Annamaria Cola. Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly. Expert review of endocrinology & metabolism. vol 12. issue 1. 2019-11-20. PMID:30058878. |
area covered: this review focuses on the role of medical therapy of acromegaly, comparing the efficacy of somatostatin analogues (ssa), dopamine-agonists (da) and pegvisomant (peg), the three available drug classes for treating acromegaly. |
2019-11-20 |
2023-08-13 |
Not clear |
| Katharina Schilbach, Jochen Schopoh. Update on the use of oral octreotide therapy for acromegaly. Expert review of endocrinology & metabolism. vol 11. issue 4. 2019-11-20. PMID:30058923. |
somatostatin analogs are most commonly used in pharmacological treatment of acromegaly. |
2019-11-20 |
2023-08-13 |
Not clear |
| Odelia Cooper, Yona Greenma. Dopamine Agonists for Pituitary Adenomas. Frontiers in endocrinology. vol 9. 2019-11-20. PMID:30186234. |
in cushing's disease, da therapy results in normalization of urinary cortisol levels in approximately 25% of patients, but reported rates of tumor shrinkage are very low; in acromegaly, da therapy leads to normalization of insulin-like growth factor i and tumor shrinkage in approximately one-third of patients, and improved responses when used in combination with somatostatin receptor ligands. |
2019-11-20 |
2023-08-13 |
Not clear |